These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19920815)

  • 1. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
    Bassa P; Kim EE; Inoue T; Wong FC; Korkmaz M; Yang DJ; Wong WH; Hicks KW; Buzdar AU; Podoloff DA
    J Nucl Med; 1996 Jun; 37(6):931-8. PubMed ID: 8683314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
    Dose Schwarz J; Bader M; Jenicke L; Hemminger G; Jänicke F; Avril N
    J Nucl Med; 2005 Jul; 46(7):1144-50. PubMed ID: 16000283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
    Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
    Schelling M; Avril N; Nährig J; Kuhn W; Römer W; Sattler D; Werner M; Dose J; Jänicke F; Graeff H; Schwaiger M
    J Clin Oncol; 2000 Apr; 18(8):1689-95. PubMed ID: 10764429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging.
    Chan SC; Ng SH; Chang JT; Lin CY; Chen YC; Chang YC; Hsu CL; Wang HM; Liao CT; Yen TC
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1032-40. PubMed ID: 16622711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
    Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
    Rousseau C; Devillers A; Sagan C; Ferrer L; Bridji B; Campion L; Ricaud M; Bourbouloux E; Doutriaux I; Clouet M; Berton-Rigaud D; Bouriel C; Delecroix V; Garin E; Rouquette S; Resche I; Kerbrat P; Chatal JF; Campone M
    J Clin Oncol; 2006 Dec; 24(34):5366-72. PubMed ID: 17088570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
    Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
    Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
    Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
    Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study.
    Tiling R; Linke R; Untch M; Richter A; Fieber S; Brinkbäumer K; Tatsch K; Hahn K
    Eur J Nucl Med; 2001 Jun; 28(6):711-20. PubMed ID: 11440031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of 18F-FDG gamma camera PET, mammography and ultrasonography in demonstrating primary disease in locally advanced breast cancer.
    Marshall C; Mustafa S; Wheatley DC; Eremin JE; El-Sheemy M; Jibril JA; Eremin O; Griffiths PA
    Nucl Med Commun; 2004 Jul; 25(7):721-5. PubMed ID: 15208500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
    Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
    Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
    Choi M; Heilbrun LK; Venkatramanamoorthy R; Lawhorn-Crews JM; Zalupski MM; Shields AF
    Am J Clin Oncol; 2010 Jun; 33(3):257-61. PubMed ID: 19806035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer.
    García Vicente AM; Cruz Mora MÁ; León Martín AA; Muñoz Sánchez Mdel M; Relea Calatayud F; Van Gómez López O; Espinosa Aunión R; Gonzalez Ageitos A; Soriano Castrejón A
    Tumour Biol; 2014 Nov; 35(11):11613-20. PubMed ID: 25139100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.